A Phase II Study of RAD001 (Everolimus) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas

Trial Profile

A Phase II Study of RAD001 (Everolimus) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Feb 2016

At a glance

  • Drugs Everolimus (Primary)
  • Indications Glioma
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Dec 2012 Additional lead trial centre added as reported by ClinicalTrials.gov.
    • 25 May 2010 New source identified and integrated (Memorial Sloan-Kettering Cancer Center ).
    • 01 Jul 2009 Planned number of patients changed from 46 to 23 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top